Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3200882 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY3200882 Schedule 1 Escalation | EXPERIMENTAL | - |
| LY3200882 Schedule 2 Escalation | EXPERIMENTAL | - |
| LY3200882 Schedule 1 Expansion | EXPERIMENTAL | - |
| LY3200882 Schedule 2 Expansion | EXPERIMENTAL | - |
| LY3200882 + LY3300054 | EXPERIMENTAL | - |
| LY3200882 + Gemcitabine + nab-Paclitaxel | EXPERIMENTAL | - |
| LY3200882 + Cisplatin + Radiation | EXPERIMENTAL | - |
| Japanese Arm LY3200882 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LY3200882 | DRUG | Administered orally |
| LY3300054 | DRUG | Administered intravenously |
| Gemcitabine | DRUG | Administered intravenously |
| nab-Paclitaxel | DRUG | Administered intravenously |
| Cisplatin | DRUG | Administered intravenously |
| Intensity Modulated Radiotherapy | RADIATION | - |
Inclusion Criteria: * The participant must have histological or cytological evidence of cancer. * Have adequate organ function. * Have Eastern Cooperative Oncology Group (ECOG) scale performance status of 0 or 1. * Are able to swallow capsules and tablets. Exclusion Criteria: * Have moderate or s...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
LY3200882 is an investigational small molecule being studied for the treatment of solid tumors. It is in Phase 1 clinical development in oncology and has not been approved for any indication. The single trial listed is evaluating it in adult participants with solid tumors.
LY3200882 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the Phase 1 solid tumor study of the compound.
LY3200882 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA or any other regulatory agency. The Phase 1 trial is currently active but not recruiting.
LY3200882 is being studied in one clinical trial, NCT02937272, titled A Study of LY3200882 in Participants With Solid Tumors. The trial is Phase 1, active but not recruiting, and has enrolled 223 participants across the United States, Australia, Canada, France, Germany, Italy, Japan, and Spain.
LY3200882 is a small molecule, but its specific molecular target is not stated in the available information. It is being developed as an oncology agent for solid tumors.